NCT05126160 Immune Score Based Radiomics in Nasopharyngeal Carcinoma
| NCT ID | NCT05126160 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Zhejiang Cancer Hospital |
| Condition | Nasopharyngeal Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 494 participants |
| Start Date | 2021-11-05 |
| Primary Completion | 2022-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 494 participants in total. It began in 2021-11-05 with a primary completion date of 2022-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In nasopharyngeal carcinoma (NPC), tumor, node and metastasis (TNM) staging system is the main tool for determining treatment strategy and assessment of prognosis. However, the prognoses of patients with the same TNM stage after similar treatment vary widely. The aim of this study is to establish an immune score based radiomic staging system for NPC.
Eligibility Criteria
Inclusion Criteria: Patients with newly histologically confirmed non-keratinizing/keratinizing carcinoma. ECOG Performance status: 0-1 With normal liver function test (ALT, AST ≤2.5ULN) Renal: creatinine clearance ≥60ml/min Without hematopathy,marrow: WBC \>4\*109/L, HGB\>90G/L, and PLT\>100\*109/L. Written informed consent Exclusion Criteria: Contraindications for MRI scan Prior malignancy (except adequately treated carcinoma in-situ of the cervix or · basal/squamous cell carcinoma of the skin) Previous chemotherapy or radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment volume) Patient is pregnant or lactating Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose \>1.5×ULN), or emotional disturbance.
Contact & Investigator
Xiaozhong Chen
PRINCIPAL INVESTIGATOR
Department of Radiation Oncology, Zhejiang Cancer Hospital
Frequently Asked Questions
Who can join the NCT05126160 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Nasopharyngeal Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05126160 currently recruiting?
Yes, NCT05126160 is actively recruiting participants. Contact the research team at cxzfyun@sina.com for enrollment information.
Where is the NCT05126160 trial being conducted?
This trial is being conducted at Wuhan, China, Ningbo, China, Ningbo, China, Wenzhou, China and 1 additional location.
Who is sponsoring the NCT05126160 clinical trial?
NCT05126160 is sponsored by Zhejiang Cancer Hospital. The principal investigator is Xiaozhong Chen at Department of Radiation Oncology, Zhejiang Cancer Hospital. The trial plans to enroll 494 participants.